Top Page
CStone Pharmaceuticals
(2616)
CStone Pharmaceuticals (2616) vs. iShares MSCI Hong Kong ETF (EWH)
CStone Pharmaceuticals Business Overview & Revenue Model
CStone Pharmaceuticals Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 177.77M | 407.20M | 463.84M | 481.36M | 243.72M | 1.04B |
| Gross Profit | 21.73M | 240.15M | 304.30M | 278.38M | 136.89M | 797.41M |
| EBITDA | -216.63M | -76.43M | -297.23M | -849.66M | -1.90B | -1.20B |
| Net Income | -242.00M | -91.21M | -367.23M | -902.68M | -1.92B | -1.22B |
Balance Sheet | ||||||
| Total Assets | 1.19B | 1.39B | 1.66B | 1.64B | 2.27B | 3.76B |
| Cash, Cash Equivalents and Short-Term Investments | 690.10M | 672.94M | 1.05B | 1.04B | 1.73B | 3.39B |
| Total Debt | 391.37M | 355.97M | 363.45M | 286.29M | 174.20M | 83.86M |
| Total Liabilities | 876.86M | 1.03B | 1.21B | 1.19B | 1.06B | 808.29M |
| Stockholders Equity | 315.04M | 363.87M | 456.83M | 449.33M | 1.21B | 2.95B |
Cash Flow | ||||||
| Free Cash Flow | -156.05M | -343.18M | -653.89M | -714.29M | -1.63B | -579.52M |
| Operating Cash Flow | -156.05M | -343.18M | -588.84M | -612.47M | -1.48B | -508.07M |
| Investing Cash Flow | -149.95M | -247.68M | 619.61M | 365.12M | -826.55M | 1.18B |
| Financing Cash Flow | 22.58M | -12.90M | 388.36M | 28.47M | 92.30M | 1.39B |
CStone Pharmaceuticals Technical Analysis
CStone Pharmaceuticals Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
57 Neutral | HK$9.79B | 51.45 | 6.73% | ― | 23.37% | ― | |
53 Neutral | HK$10.65B | 41.67 | 13.34% | ― | 206.58% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$12.36B | 18.94 | 35.80% | ― | 59.70% | 239.97% | |
42 Neutral | HK$8.41B | -18.58 | -95.84% | ― | -55.64% | -158.67% | |
41 Neutral | HK$1.90B | -2.69 | -129.05% | ― | ― | -18.99% |
CStone Pharmaceuticals Corporate Events
CStone Pharmaceuticals announced the inclusion of GAVRETO® (pralsetinib) in China’s National Reimbursement Drug List (NRDL), effective January 1, 2026. This inclusion marks a significant milestone for CStone, enhancing its market presence in Greater China and potentially increasing accessibility for patients with RET fusion-positive cancers. The drug, developed in collaboration with Blueprint Medicines, is already approved in several regions, including the U.S., Hong Kong, and Taiwan, for treating specific types of cancer, and this development is expected to strengthen CStone’s position in the oncology sector.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
CStone Pharmaceuticals announced that the European Commission has approved sugemalimab as a monotherapy for adult patients with unresectable stage III non-small cell lung cancer (NSCLC) with specific genetic profiles. This approval expands sugemalimab’s indication to cover a broader spectrum of NSCLC, providing a new treatment option for patients in Europe. The achievement highlights CStone’s commitment to enhancing global accessibility of its therapies and addressing unmet medical needs in oncology.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
CStone Pharmaceuticals has announced the international debut of its bispecific antibody, CS2015, at the 2025 Annual Scientific Meeting of the American College of Allergy, Asthma and Immunology (ACAAI). This marks the first presentation of CS2015 at an international conference, highlighting its potential impact on the treatment of type 2 inflammation. The molecule’s unique design targets OX40L and TSLP, crucial regulators of inflammation, and offers a strong developability profile for scalable manufacturing, indicating significant advancements in therapeutic options for autoimmune and inflammatory diseases.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$6.00 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
CStone Pharmaceuticals announced the approval of their Investigational New Drug application by the China National Medical Products Administration for Phase II clinical trials of CS2009, a tri-specific antibody targeting PD-1, VEGF, and CTLA-4, for advanced solid tumors. This approval is expected to accelerate the clinical development of CS2009, which is currently enrolling patients in Australia and will soon expand to China and the United States, potentially strengthening CStone’s position in the biopharmaceutical industry and offering new therapeutic options for various cancers.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
CStone Pharmaceuticals announced the composition of its board of directors, highlighting the roles and functions of each member. This announcement is significant for stakeholders as it outlines the leadership structure and governance, which can impact the company’s strategic direction and operational efficiency.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
CStone Pharmaceuticals has announced the appointment of Ms. Fang Xie as an independent non-executive director and chairperson of the audit committee, effective November 1, 2025. Ms. Xie brings over 30 years of experience in operational finance and management consulting, having served in various leadership roles in prominent companies. Her appointment follows the resignation of Ms. Yip Betty Ho, who stepped down to focus on personal commitments. The changes in the board are expected to strengthen CStone’s governance and strategic direction, potentially impacting its market positioning positively.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
CStone Pharmaceuticals announced that its CEO, Dr. Jianxin Yang, along with senior management, has increased their shareholding in the company by purchasing 1,000,000 shares, with Dr. Yang acquiring 700,000 shares. This move underscores their confidence in the company’s long-term investment value and growth prospects, as well as their commitment to its future business success. The board views this increase in shareholding as a sign of strong belief in the company’s ability to maintain steady operations and achieve rapid growth, which could positively impact stakeholder confidence.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
CStone Pharmaceuticals announced the first disclosure of preliminary Phase I data for CS2009, a PD-1/VEGF/CTLA-4 trispecific antibody, at the 2025 ESMO Annual Congress. The study, conducted in Australia and China, evaluates the safety and antitumor activity of CS2009 in patients with advanced solid tumors, showing favorable safety and tolerability with no dose-limiting toxicity reported. This development marks a significant step in CStone’s efforts to innovate cancer treatment, potentially enhancing its industry positioning and offering new hope for stakeholders involved.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
CStone Pharmaceuticals announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending the approval of sugemalimab as a monotherapy for unresectable stage III non-small cell lung cancer (NSCLC) in Europe. This development, based on the pivotal Phase III GEMSTONE-301 study, could solidify sugemalimab’s role as a core immunotherapy for lung cancer, enhancing its market presence and commercial potential. If approved, it will become the second PD-(L)1 antibody available in Europe for stage III NSCLC, addressing a critical unmet need and bringing new hope to patients.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.
CStone Pharmaceuticals announced its participation in the 2025 European Society for Medical Oncology Congress, where it will present data from its ongoing clinical trials. The company will showcase the world’s first clinical data for a PD-1/VEGF/CTLA-4 trispecific antibody, CS2009, in advanced solid tumor patients, and provide an update on the ROR1-targeting ADC, CS5001. These presentations highlight CStone’s commitment to advancing innovative cancer therapies and may enhance its positioning in the biopharmaceutical industry.
The most recent analyst rating on (HK:2616) stock is a Hold with a HK$7.50 price target. To see the full list of analyst forecasts on CStone Pharmaceuticals stock, see the HK:2616 Stock Forecast page.